Q3 EPS Estimate for Ironwood Pharmaceuticals Cut by Analyst

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research dropped their Q3 2026 EPS estimates for Ironwood Pharmaceuticals in a report released on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.07 per share for the quarter, down from their previous estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The business had revenue of $90.55 million during the quarter, compared to analysts' expectations of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.

Several other equities research analysts have also issued reports on the stock. JMP Securities decreased their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th. Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.60.

Ironwood Pharmaceuticals Stock Down 3.1 %

IRWD traded down $0.05 during trading on Friday, hitting $1.43. 323,299 shares of the company traded hands, compared to its average volume of 2,418,989. The firm has a market cap of $228.04 million, a P/E ratio of -47.17 and a beta of 0.37. Ironwood Pharmaceuticals has a one year low of $1.32 and a one year high of $8.64. The stock's fifty day moving average is $2.00 and its 200 day moving average is $3.36.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds have recently made changes to their positions in IRWD. Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after buying an additional 450,949 shares during the last quarter. State Street Corp lifted its holdings in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 23.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company's stock valued at $7,846,000 after purchasing an additional 364,841 shares in the last quarter. FMR LLC raised its position in Ironwood Pharmaceuticals by 25.1% in the 3rd quarter. FMR LLC now owns 169,681 shares of the biotechnology company's stock worth $699,000 after purchasing an additional 34,089 shares during the period. Finally, Weiss Asset Management LP bought a new stake in Ironwood Pharmaceuticals in the third quarter worth $893,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.